Viridian Therapeutics, Inc.\DE 8-K

What Happened

• Viridian Therapeutics, Inc. (VRDN) announced its financial results for the fourth quarter and full year ended December 31, 2025. The company issued a press release dated February 26, 2026 reporting these results; that press release is attached to the company's Form 8-K as Exhibit 99.1.

Key Details

• Filing date: February 26, 2026 (Form 8-K, Items 2.02 and 9.01).
• Reporting period: Quarter and year ended December 31, 2025.
• Exhibit: Press release furnished as Exhibit 99.1 to the 8-K.
• Interactive data: Cover Page Interactive Data File included in Inline XBRL (Exhibit 104).

Why It Matters

• This 8-K provides the company’s most recent earnings and operating results, which investors use to assess revenue, expenses, cash position and progress on clinical or product programs. The attached press release is the definitive source of the reported figures and any accompanying commentary or guidance.
• Retail investors should review Exhibit 99.1 (or the company’s investor relations materials/SEC Edgar filing) to see the specific numbers and management commentary to evaluate Viridian’s financial health and near-term outlook.